Changes in Glucose Metabolism and Blood Flow Following Chemotherapy for Breast Cancer

Mankoff, David A.; Dunnwald, Lisa K.

doi:10.1016/j.cpet.2005.09.001

Cited by 19 publications

(11 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the earliest studies of 18 F-FDG PET to measure response was performed by Wahl et al (21) and showed significant quantitative differences in the 18 F-FDG uptake measured before and after 2 mo of therapy for responders versus nonresponders. Almost all of the subsequent studies reported similar findings and found that a primary tumor 18 F-FDG uptake decline by approximately 50% or more was predictive of a good response (17,22). Perhaps more important, lesser declines in 18 F-FDG uptake predicted poor response.…”

Section: Overviewsupporting

confidence: 60%

“…Another study by Berriolo-Riedinger reported similar findings (28). These findings suggest that 18 F-FDG PET may serve as an early predictor of chemotherapy response and, importantly, as an accurate predictor of lack of response, which is clinically relevant given the increasing number of new medical therapies available for breast cancer.Studies performed after the completion of chemotherapy have shown that although residual 18 F-FDG uptake predicts residual disease, the absence of 18 F-FDG uptake is not a reliable indicator of pCR (17,(29)(30)(31). This is especially true for axillary nodal disease, because the sensitivity for residual microscopic disease after therapy is low.…”

mentioning

confidence: 96%

“…Studies of 18 F-FDG PET comprise the largest body of work on radiotracer imaging for response evaluation to neoadjuvant breast cancer treatment (17)(18)(19). Some of the earliest work using 18 F-FDG to monitor cancer response was done in this clinical setting (20,21).…”

Section: Response To Therapy Overviewmentioning

confidence: 99%

“…Some of the earliest work using 18 F-FDG to monitor cancer response was done in this clinical setting (20,21). Serial 18 F-FDG PET has been widely studied as a method for assessing tumor response to neoadjuvant chemotherapy, using a comparison to histopathology assessment of response from the postsurgery specimen as the gold standard (17,22). In these studies, 18 F-FDG PET scans were obtained before therapy and then at 2 or more time points (early [after a single cycle of therapy], mid-therapy, and after therapy) during the course of neoadjuvant therapy (Fig.…”

Section: Response To Therapy Overviewmentioning

confidence: 99%

“…Sized-based approaches for response evaluation, for example, physical examination and mammography, have not performed well in this setting and have trouble distinguishing pCR from other responses (8,9). This is, therefore, a role in which functional imaging may be particularly helpful.Studies of 18 F-FDG PET comprise the largest body of work on radiotracer imaging for response evaluation to neoadjuvant breast cancer treatment (17)(18)(19). Some of the earliest work using 18 F-FDG to monitor cancer response was done in this clinical setting (20,21).…”

mentioning

confidence: 99%

See 4 more Smart Citations

The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2—Response to Therapy, Other Indications, and Future Directions

Lee

Rosen²,

Mankoff³

2009

J Nucl Med

Self Cite

View full text Add to dashboard Cite

and 2 Seattle Radiologists, Seattle, Washington Breast cancer is the most common non-skin type of cancer and the second leading cause of cancer mortality in women. Advances in diagnosis and treatment have led to declines in mortality, despite an increase in breast cancer incidence. An advancing array of both local and systemic therapy options has led to increasingly individualized treatment. Imaging plays a key role in detecting breast cancer and directing its therapy. This continuing education article provides a comprehensive review of current and future radiotracer imaging methods applied to breast cancer, in the context of breast cancer management strategies and other nonnuclear imaging methods. Part 1 of the review provided an overview of clinical and biologic considerations in breast cancer and covered radionuclide imaging for detection and staging. Part 2 covers radionuclide imaging of breast cancer response to therapy, other clinical indications for radionuclide breast cancer imaging, and future directions, including molecular imaging.Key Words: breast cancer; response to therapy; continuing education; molecular imaging; radionuclide imaging J Nucl Med 2009; 50:738-748 DOI: 10.2967/jnumed.108.061416 Breastcanceri s the most common non-skin type of cancer and the second leading cause of cancer mortality in women (1). Although its incidence continues to rise, mortality has declined over the past several years (1,2). The decline has been attributed to both early diagnosis and more effective treatment (2). Advances in molecular cancer biology have led to an increased understanding of the biologic factors that contribute to breast cancer pathogenesis and progression. This understanding has already led to new and effective treatments (3), and new targeted therapies continue to be developed and tested (4). Advances in breast cancer molecular biology have also yielded improvements in diagnosis through molecular pathology and molecular imaging (5,6).Part 1 of this review provided an overview of breast cancer clinical features and biology and reviewed radionuclide imaging for breast cancer detection and staging. Part 2 reviews applications to therapeutic monitoring and other indications such as toxicity monitoring, followed by highlights of future directions, including that of molecular imaging. RESPONSE TO THERAPY OverviewA wide range of systemic therapy options for breast cancer exists, and breast cancer is one of the more responsive solid tumors (7). Therefore, the evaluation of response to therapy is an important diagnostic need for breast cancer. Systemic therapy is given in 1 of the 3 following clinical settings: adjuvant (after completion of definitive locoregional surgery to treat residual or metastatic microscopic disease), neoadjuvant (primary systemic therapy given before definitive local surgery), or metastatic (systemic therapy of stage IV disease).For adjuvant therapy, there should be no residual macroscopic disease after surgery and, therefore, imaging is not helpful for response monitoring, exce...

show abstract

Section: Overviewsupporting

confidence: 60%

mentioning

confidence: 96%